Diversified harmony: Supranational and domestic regulation of pediatric clinical trials in the European Union  by Pinxten, Wim et al.
Journal of Cystic Fibrosis Volume 10 Suppl 2 (2011) S183–S198
www.elsevier.com/locate/jcf
Diversiﬁed harmony:
Supranational and domestic regulation of pediatric clinical trials
in the European Union
Wim Pinxten *, Kris Dierickx, Herman Nys
Centre for Biomedical Ethics and Law, K.U. Leuven, BE-3000 Leuven, Belgium
Abstract
Over the past decades, considerable legislative effort has been made to facilitate and encourage clinical research in the European Union
(EU). Hereby, speciﬁc attention has been paid to the urgent need to conduct research in minors. In this article, we will analyze the regulation
that currently governs pediatric clinical research conduct at the supranational level of the EU and at the level of individual EU member states.
Our analysis will focus on the way in which the national and supranational legal frameworks address ﬁve ethical issues that are speciﬁc
to pediatric clinical research: (a) informed consent, (b) the necessity to conduct research in minor subjects, (c) the interests of the subject
concerned, (d) the risks and burdens involved, and (e) the pediatric expertise of protocol review committees. We conclude by discussing the
harmonization and diversiﬁcation of the legal requirements that govern pediatric clinical research in the EU.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Safe and efﬁcacious drugs cannot be provided to those
in need without the conduct of clinical research. Over the
past decades, considerable legislative effort has been made
to facilitate and encourage the conduct of clinical research
in the European Union (EU). Hereby, speciﬁc attention has
been paid to the urgent need to conduct research in small and
vulnerable populations in general and minors in particular.
At present, pediatrics is still hampered by a stringent lack
of licensed drugs that are labeled for pediatric use. Although
minors have been designated as therapeutic orphans ever since
this phenomenon was ﬁrst described in 1968 [1], the gamut of
approved medicines for use in children remains considerably
smaller than that available to adults [2–4]. Nonetheless,
catching up with pediatric research is a precarious enterprise,
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and several constraints render the conduct of clinical studies
in minor subjects complicated and expensive [5].
In the speciﬁc case of cystic ﬁbrosis, the conduct of
clinical research in minor subjects is particularly valuable for
several reasons. First, starting with preventive and therapeutic
measures at an early stage of the disease is an important
asset because the pathology of cystic ﬁbrosis develops over
time. Therefore, the disease will have caused less irreversible
damage to the body in young children than in adults, and early
intervention may open up additional therapeutic opportunities.
Second, the treatment of CF involves considerable drug
intake, also for minors. The availability of safe and efﬁcacious
drugs is thus of great importance to minors suffering from
CF. In addition, clinical trials may result in a reduction of
the number of drugs that CF patients need to take, and thus
reduce the burden of the – often harsh – therapeutic scheme.
Third, the number of patients with CF is relatively large,
rendering the population a good candidate for the conduct of
pediatric clinical research. The population of CF minors is
not too small to compound representative samples of research
subjects, and the market for newly tested medicines can be
large enough to make research ﬁnancially viable.
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Obviously, the conduct of clinical research in the vulner-
able population of minors generates abundant, diverse, and
speciﬁc ethical issues. Nonetheless, these issues have increas-
ingly been addressed in the ethical and legal frameworks that
currently govern clinical research in the EU [5].
In this article, we will analyze the regulation that currently
governs pediatric clinical research conduct at the suprana-
tional level of the EU and at the level of individual EU
member states. Our analysis will focus on the way in which
the national and supranational legal frameworks address ﬁve
ethical issues that are speciﬁc to pediatric clinical research:
(a) informed consent, (b) the necessity to conduct research in
minor subjects, (c) the interests of the subject concerned, (d)
the risks and burdens involved, and (e) the pediatric expertise
in committees that review research protocols for pediatric
studies. Our analysis concludes with a discussion of the
harmonization and diversiﬁcation of the legal requirements
that govern pediatric clinical research in the European Union.
2. Scope, materials and methods
In this article, the supranational and national legal frame-
works that govern pediatric clinical research in the EU are
investigated. Several criteria were used to determine the scope
of our analysis. First, our analysis is limited to legislation that
was issued under the responsibility of either the European
Union, the Council of Europe, or by a legislative body of
an individual EU Member State. Second, only legal regu-
lations fall within the scope of our analysis. Ethical codes
that were not promulgated by a legislative body, such as the
Declaration of Helsinki, are thus not taken into account, even
though these codes may have considerable (moral) authority.
Third, to be part of our analysis, regulation must concern
the ethics of pediatric research conduct, and thus be related
to good clinical practice in pediatric research conduct or the
encouragement and facilitation of pediatric clinical research.
Therefore, purely administrative requirements fall outside the
scope of our analysis, even when they are speciﬁc to pedi-
atric research. Likewise, the general requirements for good
clinical practice in research conduct that are also applicable
to other patient populations will not explicitly be part of our
analysis, even though these requirements are often applicable
to research in minor subjects. Also the general procedures of
protocol approval by ethics committees or competent authori-
ties in individual EU member states will not be the subject of
our analysis, as such analysis was already published elsewhere
[6,7].
At the supranational level, the Clinical Trial Directive
(Directive 2001/20/EC of the European Parliament and of the
Council of 4 April 2001 on the approximation of laws, reg-
ulations and administrative provisions of the member states
in relation to the implementation of good clinical practice
in the conduct of clinical trials on medicinal products for
human use) functions as the centerpiece of a wider regulatory
framework [8]. In addition to the Clinical Trial Directive,
the Pediatric Regulation (Regulation (EC) No 1901/2006 of
the European Parliament and of the Council of 12 December
2006 on medicinal products for paediatric use and amending
Regulation (EEC) No 1768/92, Directive 2001/20/EC, Direc-
tive 2001/83/EC and Regulation (EC) No 726/2004) is highly
relevant for the conduct of pediatric clinical research in EU
Member states [9]. This regulation discusses the conduct of
ethical research and aims to encourage and reward the conduct
of pediatric clinical research. Third, the Council of Europe
Convention on Human Rights and Biomedicine (European
Convention for the protection of Human Rights and dignity of
the human being with regard to the application of biology and
medicine, Oviedo 1997, further the European Convention) is
binding upon the EU member states that respectively signed
and ratiﬁed the Convention [10]1. In 2005, the European
Convention was supplemented with an additional protocol on
biomedical research (Additional Protocol to the Convention
on Human Rights and Biomedicine, concerning Biomedical
Research, Strasbourg, 25.I.2005), which is binding upon the
member states that signed and ratiﬁed this additional protocol
[11]2.
In addition to our analysis of supranational regulation,
we analyzed the domestic legislation that implements the
Clinical Trial Directive into the national law of individual EU
member states. Table 1 offers an overview of national laws
implementing the Clinical Trial Directive. The original texts
of domestic laws, acts, decrees, or regulations that implement
the Clinical Trial Directive into national law entail different
legal systems (civil law and common law) and are issued
in no less than 22 different languages. Our analysis covers
original texts in four languages (English, French, German,
and Dutch). In addition, (most often unauthorized) English
translations of national laws were consulted, and in one case,
a native speaker was called upon to gather information where
no translation was accessible3.
For 24 EU Member States, the text of the national law
that implements the Clinical Trial Directive could be analyzed
in its original language or via an (unauthorized) English
translation. Speciﬁc regulations arranging the operational
implementation of national laws (e.g. (royal) decrees, orders,
circulars), however, were often difﬁcult or impossible to
access in English. Therefore, these documents will not
exhaustively be part of the analysis presented in this article.
For three countries, there was no English translation of
the national law implementing the European Clinical Trial
Directive available (Cyprus, Hungary, and Slovenia). For these
countries, the analysis in this article is based on secondary
sources, in so far that such information could be traced.
1 For an overview of countries that signed and ratiﬁed the Euro-
pean Convention, see: http://conventions.coe.int/Treaty/Commun/ChercheSig
.asp?NT=164&CM=&DF=&CL=ENG (accessed 1 December 2009)
2 For an overview of countries that signed and ratiﬁed the European
Convention’s Additional Protocol concerning Biomedical Research, see:
http://conventions.coe.int/Treaty/Commun/ChercheSig.asp?NT=195&CM=7
&DF=03/12/2009&CL=ENG (accessed 1 December 2009)
3 The authors are grateful to Zuzanna Osewska for the analysis and transla-
tion of the Polish law.
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Table 1
Overview of the national laws implementing the European Clinical Trial Directive
Country Domestic implementation of Directive 2001/20/EC* Article
Austria Drug Law (1983, amended 29 April 2004 to implement Directive 2001/20/EC) §42(1)
Belgium Law concerning experiments on the human person (7 May 2004) Art. 7
Bulgaria Medicinal Products in Human Medicine Act (13 April 2007). Art 97, 100
Regulation No. 31 on the Rules for GCP (12 August 2007) is applicable.
Cyprus –
Czech Republic Act on Pharmaceuticals and on Amendments to Some Related Acts (the Act on Pharmaceuticals, 6 December
2007).
Section 52
Decree on good clinical practice and detailed conditions of clinical trials on medicinal products (23 June 2008). Section 8 (5)
Denmark Act on a Scientiﬁc Ethical Committee System and the Processing of Biomedical Research Projects (28 May
2003).
Art. 17
Art. 19
Estonia Medicinal Products Act (16 December 2004). §91
Germany Medicinal Products Act (12 December 2005). Chapter 6, Section
40(4) and 41(2)
Finland Medical Research Act No. 488/1999 (23 April 2004). Section 8
France Law no. 2004-806 of 9 August 2004 concerning public health policy 1121–1122
Greece Law no. DYG 3/89292 on the harmonization of the Hellenic Legislation to the respective Community legislation
in compliance with Directive 2001/20/EC of 4 April 2001 “on the approximation of the legislative, regulatory and
administrative provisions of the Member States regarding the implementation of Good Clinical Practice (GCP) in
clinical trials on medicinal products for human use” (12 December 2005).
Art. 4
Hungary Health Ministry Decree EüM24/2002 on the clinical trial of medicinal products for human use and on Good
Clinical Practice
Ireland Statutory Instrument No. 190 of 2004 (European Communities (Clinical Trials on Medicinal Products for Human
Use) Regulations (29 April 2004).
Part 4
Italy Legislative Decree no. 211 concerning the transposition of Directive 2001/20/EC relating to the implementation of
good clinical practice in the conduct of clinical trials on medicinal products for clinical use (24 June 2003)
Section 4
Latvia Cabinet Regulation No 172 Regulations on Conducting Clinical Trials and Non-interventional studies and
Labeling of Investigational Medicinal Products, and Procedure for Conducting Inspections on Compliance with
the Requirements of Good Clinical Practice (28 February 2006).
Art. 30
Lithuania Health Care Ministry Decree on the Implementation of the Rules of Good Clinical Practice, which implemented
Directive 2001/20/EC (11 May 2004).
Law on Ethics of Biomedical Research (11 May 2000). Art. 7
Luxembourg Grand Ducal Regulation concerning the application of good clinical practice in the conduct of clinical trials of
medicines for human use (Clinical Trials of Medicines for Human Use, 30 May 2005).
Art. 4
Art. 6
Malta Amended Medicines Act (Medicines act to make provision for matters connected with the manufacture,
preparation and assembly, wholesale distribution, storage, destruction, disposal, advertising and authorization of
medicinal products and any activity connected therewith and the regulation of the sale of medicinal products,
pharmacies and related pharmaceutical activities and for any other matters ancillary thereto or connected
therewith, 21 November 2003)
Art. 18.2.
Netherlands Amended Medicinal Research involving Human Subjects Act (Regulations on medical research involving human
Subjects, 1 March 2006).
Section 6
Poland Resolution of the Senate of the Republic of Poland of 16 April 2004, amending the Pharmaceutical Law and the
Act on the Profession of the Medical Doctor
Portugal Law no. 46/2004 concerning Clinical Trials on Medicinal Products for Human Use (19 August 2004). Art. 7
Romania Ministry of Health order No. 904/25.07.2006 on approval of rules relating to the implementation of good clinical
practice in the conduct of clinical trials on medicinal products for human use
Slovakia Ministerial Decree on clinical trials and Good Clinical Practice (1 May 2004). Art. 15b
Slovenia –
Spain Royal Decree 223/2004 regulating clinical trials with medicinal products (6 February 2004). Art. 4
Art. 7,3
Sweden Act concerning the Ethical Review of Research Involving Humans (5 June 2003). Section 18
United Kingdom Medicines for Human Use (Clinical Trials) Regulations (Statutory Instrument 2004 No. 1031, 31 March 2004). Part 4
* The document named in the list is the main law, act or regulation implementing the Clinical Trial Directive into the national law of the member state
concerned, that has explicitly been drafted to implement the Clinical Trial Directive. It is important to acknowledge that other laws, acts or regulations that are
complementary to the named document(s) in the regulation of pediatric research may exist.
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3. Ethical issues addressed in the legal frameworks
Five major ethical issues in pediatric clinical research
conduct are addressed in the European legal frameworks
governing pediatric research: (a) informed consent, (b) the
necessity to conduct research in minors, (c) the interests of
the research subject in the study concerned, (d) the risks and
burdens involved, and (e) the pediatric expertise of ethics
committees reviewing protocols for clinical studies in minors.
3.1. Informed consent
Ever since the research scandals during the Second World
War and its aftermath, the principle of respect for persons
has been adopted steadfastly in inﬂuential ethical guidelines
and legal regulations. Traditionally, this principle has been
made operational in the ethical and legal doctrine of informed
consent.
The current paradigm of informed consent for research
participation is voluntary consent provided by a legally
competent adult after being duly informed about all relevant
aspects of the clinical trial concerned. For several reasons,
this paradigm has serious workability problems in the case
of pediatric clinical studies. First, due to age restrictions,
most minors are not capable of granting legally valid consent,
as they may not have reached the age of medical majority
(which is not necessarily the same as the age of legal
majority) [12]. Second, the capacity to understand and assess
information is often still underdeveloped in minor research
subjects. As a result, minors may lack the competence
necessary to make rational decisions and it may be difﬁcult to
inform minors duly. Third, most minors are largely dependent
upon their parents in numerous aspects of their lives. It is
widely recognized that parents enjoy considerable discretion
in educational matters, and therefore they may, to a large
extent, decide autonomously whether and to what extent their
minor children can participate in decisions about clinical trial
participation.
Due to the incompetence of minors to provide legally
valid informed consent, the involvement of a competent adult
acting as a surrogate decision maker is most often required to
enroll a minor in a clinical trial. Obviously, such involvement
of a proxy does not preclude minors from playing an active
role in decisions about clinical trial participation. Quite the
reverse, several decision making strategies, including (i) dual
consent, (ii) consent by the proxy and assent by the child, and
(iii) respect for the dissent of the child, aim at encouraging
shared decision making and a fair differentiation of decision
authority between the proxy decision maker and the minor
research subject.
3.2. Necessity to involve minors
Minors are widely regarded as a vulnerable population
that deserve extensive protection against harm and abuse.
Therefore, it is a generally accepted principle that minors
should not be exposed to the risks to harm and abuse that are
inherent to any clinical trial, unless this is strictly required
to generate relevant research results that will be of beneﬁt
to minor patients. In this respect, the large majority of
ethical codes and legal rules prohibit research from being
conducted in minors whenever alternative research methods
or (non-vulnerable) populations are available.
3.3. Interest in the research
To preclude human subjects who participate in clinical
trials being used as a means to procure a scientiﬁc end, two
principles of research conduct are generally adopted in the
ethical codes and legal regulations governing clinical research.
First, the principle that the interests of science and society
never prevail over the interests of individual research subjects
is widely endorsed in ethics and law. Second, it is widely
assumed that research should comply with the interests of
the subjects involved. However, it is important to emphasize
that these interests can be very broad and diverse, as they
may range from mere altruism to becoming one of the very
ﬁrst beneﬁciaries of a newly developed safe and efﬁcacious
treatment.
In the speciﬁc case of pediatric research, there exists a
considerable consensus that clinical research in the pediatric
population should only be undertaken in so far that the
research serves the interests of minors, either by generating a
direct beneﬁt for the minor research subject concerned, or by
yielding an indirect beneﬁt to a larger group of beneﬁciaries,
such as the population of minors or the group of patients to
which the minor belongs.
3.4. Risks and burdens
Research participation never comes without burdens, and
most often accepting a certain degree of risk is essentially
part of participating in a clinical trial. Deciding upon the
acceptability of the risks and burdens inherent to research
participation, however, is often a complex and difﬁcult issue,
particularly when research is conducted in a vulnerable
population such as minors.
Throughout the recent history of pediatric clinical research,
the ethical acceptability of research risks has been the subject
of considerable debate [13]. Excluding minors from research
participation altogether may be considered the most effective
way to protect minors from research risks. However, the
practical outcome of such a stance is devastating, because it
leads minors to become therapeutic orphans [1]. Therefore,
alternate ways have been sought to keep minors from unac-
ceptable research risks. At the present time, risk thresholds
often play a prominent role in the assessment of the ethical
acceptability of pediatric clinical trials [14–17]. As a general
rule, research in minors will increasingly be considered to
be acceptable as the risks involved decrease. In addition, it
is a widely supported premise that, to a considerable extent,
the beneﬁts generated by clinical research justify the risks
involved.
Several principles guide the assessment of this risk–beneﬁt
W. Pinxten et al. / Journal of Cystic Fibrosis Volume 10 Suppl 2 (2011) S183–S198 S187
ratio. First, a principle of proportionality is used to determine
whether the risks inherent to a clinical trial are deemed
acceptable. The greater the beneﬁt to a person or group of
individuals the research is expected to yield, the more the risk
will be considered acceptable. Second, a direct beneﬁt to the
subject concerned is preferred over a beneﬁt to more remote
beneﬁciaries, such as the population of minors, the group of
patients to which the minor belongs, or a group of future
patients. As a result, the more remote the beneﬁciary, the
higher the risk threshold. Third, also the physical condition of
research subjects relates to the acceptability of research risks.
The worse the condition of a patient, the higher the risk that
will be deemed acceptable. In severe conditions, such as life
threatening diseases at an advanced stage, decision-makers,
including ethics committees, clinicians, parents, or a minor
subject will be generally prepared to accept higher risks in
research participation.
3.5. Pediatric expertise of ethics committees
Before research in minor subjects can start, the research
protocol must be reviewed and endorsed by the competent
authority and at least one ethics committee4. To guarantee an
adequate assessment of issues that are speciﬁcally related to
the conduct of clinical research in minors, ethics committees
require expertise to assess rigorously research protocols. This
pediatric expertise can be achieved in various ways, such as
fostering pediatric expertise within the ethics committee (e.g.
by having a pediatrician among the committees members), or
by consulting external expertise.
4. Regulation at the supranational level
At present, clinical research is to a considerable extent
regulated at the supranational level. At the European suprana-
tional level, the European Convention on Human Rights and
Biomedicine, the European Clinical Trial Directive, and the
Pediatric Regulation together constitute the legal framework
governing pediatric clinical trials.
4.1. European Convention on Human Rights and Biomedicine
In 1997, the European Convention was denounced by the
Council of Europe. In 2005, this Convention was supple-
mented with an additional protocol on biomedical research.
To date, the European Convention is binding upon the 14 EU
Member States (and 10 countries outside the EU) that signed
and ratiﬁed it, and its additional protocol is binding upon the
4 EU Member States (and 1 country outside the EU) that
signed and ratiﬁed it5.
The European Convention speciﬁcally addresses the issue
of pediatric research in art. 17 (Box 1). Also art. 6 and 16 are
4 Depending upon the EU member state in which the research is conducted,
the intervention of one or several ethics committees may be required [1].
5 In Finland, that recently signed and ratiﬁed the European Convention, the
European Convention will enter into force at 1 March 2010.
Box 1
European Convention on Human Rights and Biomedicine
Article 17 – Protection of persons not able to consent to
research
1. Research on a person without the capacity to consent as
stipulated in Article 5 may be undertaken only if all the
following conditions are met:
i. the conditions laid down in Article 16, sub-paragraphs i
to iv, are fulﬁlled;
ii. the results of the research have the potential to produce
real and direct beneﬁt to his or her health;
iii. research of comparable effectiveness cannot be carried
out on individuals capable of giving consent;
iv. the necessary authorisation provided for under Article 6
has been given speciﬁcally and in writing; and
v. the person concerned does not object.
2. Exceptionally and under the protective conditions pre-
scribed by law, where the research has not the potential to
produce results of direct beneﬁt to the health of the person
concerned, such research may be authorised subject to the
conditions laid down in paragraph 1, sub-paragraphs i, iii,
iv and v above, and to the following additional conditions:
i. the research has the aim of contributing, through sig-
niﬁcant improvement in the scientiﬁc understanding of
the individual’s condition, disease or disorder, to the
ultimate attainment of results capable of conferring ben-
eﬁt to the person concerned or to other persons in the
same age category or afﬂicted with the same disease or
disorder or having the same condition;
ii. the research entails only minimal risk and minimal
burden for the individual concerned.
of some relevance, as they provide details on the protection of
persons not able to consent (be it not speciﬁcally in the setting
of clinical research), and the protection of persons undergoing
research (be it not speciﬁcally minors), respectively. The
additional protocol on biomedical research touches the subject
of pediatric research in art. 17.
The European Convention’s provisions on the involvement
of minors in clinical research are related to the provision of
informed consent, the necessity to involve minors, the interest
of the research subject and the risks and burdens involved in
the study.
4.1.1. Informed consent
The European Convention provides in art 17,1iv that the
representative of the minor must grant his or her informed
consent for the enrollment of a minor subject in a clinical
trial. This authorization must be provided speciﬁcally and
in writing. According to the European Convention, it is
not required that minor research subjects provide informed
consent or assent in addition to the proxy consent provided by
the parents or another legal representative. However, the active
participation of minors in decisions is hereby not precluded.
Quite the reverse, the European Convention does not create
any hurdles to the active participation of minors in consent
discussions, and even grants minors clear decision making
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powers in the form of a veto right, as art 17,1v provides
that research can only be carried out if the minor research
subject does not object. In addition, the European Convention
provides that the opinion of minors must be taken into
consideration as an increasingly important factor in relation to
age and degree of maturity regarding therapeutic interventions
(art. 6,2). Although this requirement is provided with regard
to therapeutic interventions and is not highlighted in the
section on research intervention, respect for this requirement
is recommended in the research setting.
4.1.2. Necessity to involve minors
The European Convention endorses the principle that
minors should only take part in clinical research if similar
results cannot be obtained without their involvement, i.e.
by research not involving humans (art. 16,i) or research in
individuals capable of informed consent (art. 17,1iii).
4.1.3. Interest of the research subject
As a general rule, art. 17,1ii of the European Convention
provides that research on a person who lacks the capacity
to provide legally valid consent may only be undertaken if
“the results of the research have the potential to produce real
and direct beneﬁt to his or her health”. In absence of a real
and direct beneﬁt to the research subject concerned, the risks
and burdens are only deemed acceptable if two additional
requirements are met. First, research must aim at generating
beneﬁt to persons sharing the same age category, disease,
disorder, or condition with the participating research subject
(art. 17,2i). Second, research may only entail a minimal risk
and minimal burden to the research subject involved (art.
17,2i).
4.1.4. Risks and burdens
The European Convention explicitly links the acceptability
of risks and burdens to the beneﬁt involved. In the absence
of a direct beneﬁt to the research subject, only minimal risk
and minimal burden are deemed acceptable. The additional
protocol clariﬁes the notions “minimal risk” and “minimal
burden”, as according to art. 17 of the additional protocol, a
research intervention only entails minimal risk if the results of
that intervention generate at most a very slight and temporary
negative impact on the health of the person concerned and
entails only minimal burden if it is to be expected that
the discomfort to the research participants will be, at most,
temporary and very slight. The explanatory report illustrates
minimal risk as taking a single blood sample from a child
(Explanatory Report, §111), which implies that many clinical
trials, especially those with investigational medicinal products
and in relatively early stage of the research, are outlawed by
the European Convention.
4.2. Clinical Trial Directive
The Clinical Trial Directive mainly aims at the harmo-
nization of the provisions on good clinical practice and the
facilitation of multicentre clinical trials across the borders of
Box 2
Clinical Trial Directive (Directive 2001/20/EC)
Article 4 – Clinical trials on minors
In addition to any other relevant restriction, a clinical trial on
minors may be undertaken only if:
(a) the informed consent of the parents or legal representative
has been obtained; consent must represent the minor’s
presumed will and may be revoked at any time, without
detriment to the minor;
(b) the minor has received information according to its ca-
pacity of understanding, from staff with experience with
minors, regarding the trial, the risks and the beneﬁts;
(c) the explicit wish of a minor who is capable of forming an
opinion and assessing this information to refuse participa-
tion or to be withdrawn from the clinical trial at any time
is considered by the investigator or where appropriate the
principal investigator;
(d) no incentives or ﬁnancial inducements are given except
compensation;
(e) some direct beneﬁt for the group of patients is obtained
from the clinical trial and only where such research is
essential to validate data obtained in clinical trials on
persons able to give informed consent or by other research
methods; additionally, such research should either relate
directly to a clinical condition from which the minor
concerned suffers or be of such a nature that it can only be
carried out on minors;
(f) the corresponding scientiﬁc guidelines of the Agency have
been followed;
(g) clinical trials have been designed to minimise pain, dis-
comfort, fear and any other foreseeable risk in relation to
the disease and developmental stage; both the risk thresh-
old and the degree of distress have to be specially deﬁned
and constantly monitored;
(h) the Ethics Committee, with paediatric expertise or after
taking advice in clinical, ethical and psychosocial prob-
lems in the ﬁeld of paediatrics, has endorsed the protocol;
and
(i) the interests of the patient always prevail over those of
science and society.
individual EU Member States. All EU Member States were
bound to implement this directive into national law before
the deadline of 1 May 2004. In the national implementation
of the European Directive, EU Member States were free to
adopt stricter provisions than those set down in the European
Directive, as long as the standards of protection and time lim-
its captured in the Clinical Trial Directive were not violated
(art. 3,1). As a result, there exists considerable diversity in
the national provisions on the conduct of pediatric clinical
research across the EU. Nevertheless, several EU member
states opted for an almost verbatim implementation of the text
of the Directive6. The Clinical Trial Directive addresses the
speciﬁc issues of pediatric research in its art. 4 (Box 2).
6 Italy, Luxembourg, Malta, Portugal and Romania opted for a (nearly)
verbatim implementation of the text of the Clinical Trial Directive.
W. Pinxten et al. / Journal of Cystic Fibrosis Volume 10 Suppl 2 (2011) S183–S198 S189
In addition to the provisions of the European Directive,
the scientiﬁc guidelines of the European Medicines Agency
(EMEA) have to be followed. In this respect, speciﬁc guidance
on the implementation of the Clinical Trial Directive in
pediatric research practice was provided in the guideline
“Ethical Considerations for Clinical Trials on Medicinal
Products Conducted with the Paediatric Population” [18]. This
guideline addresses a number of important issues involving
minors in clinical trials. First, the participation of minors in
decisions on their enrollment in clinical research is addressed.
In this respect, assent, a term that is not used in the
European Directive, is recommended as a means to enable
the participation of minors in decisions. Notwithstanding this
provision, the responsibility of parents to protect the interests
of their child is emphasized.
Second, the grey zone in between legal incapacity to
consent and factual capacity to consent is addressed. It is
acknowledged that certain minors are mature enough to pro-
vide valid consent, even when they have not reached the
legal minimum age. In this respect, the guideline acknowl-
edges that “emancipated minors” must give written consent
to research participation, and that the consent of the parents
or another legal representative is not required for mature
minors. Notwithstanding this provision, it is emphasized that
mature minors can be vulnerable, and may require additional
discussions and explanations.
Like the European Convention, the Clinical Trial Directive
captures speciﬁc provisions on the involvement of minors
in clinical research (art. 4), in which the ethical concerns
of informed consent, the necessity of involving minors,
the interests of the research subject, the risks and burdens
involved, and the review of research protocols are addressed.
4.2.1. Informed consent
Art. 4a of the Clinical Trial Directive requires that consent
for research participation is given by the parents or a legal
representative. It is speciﬁed that consent “must represent
the presumed will of the minor, and may be revoked at
any time without repercussions to the minor”. In addition,
the Clinical Trial Directive serves to involve minors in
decisions on research participation by stating in art. 4b that
minors must receive information “regarding the trial, the
risks, and the beneﬁts of the trial”, in accordance with
their capacity of understanding and provided by staff with
experience with minors. Further, art. 4c provides that the
(principal) investigator must consider the explicit wish to
refuse or discontinue participation formulated by a minor who
is capable of assessing information and forming an opinion.
In the Dutch version of the Directive, however, it is stated
that the will of the minor to discontinue participation must be
respected by the principal investigator [19].
4.2.2. Necessity to involve minors
The Clinical Trial Directive provides in art. 4e that minors
should not be involved in research whenever similar results
can be obtained by research in competent adults or by other
research methods.
4.2.3. Interests of the research subject
The Clinical Trial Directive requires that the research
generates a direct beneﬁt. In art. 4e, this direct beneﬁt is
deﬁned broadly as “some direct beneﬁt” that either can be
an individual beneﬁt (to the research subject) or a group
beneﬁt (to the group of patients). In case of a group beneﬁt,
no additional requirements are applicable. In addition, this
article requires that research is related directly to “a clinical
condition from which the minor concerned suffers or be of
such nature that it can only be carried out on minors”.
The Clinical Trial Directive explicitly guards minors and
their parents against ﬁnancial persuasions, as art. 4d prohibits
all incentives or ﬁnancial inducements to stimulate research
participation, except for compensation.
4.2.4. Risks and burdens
In art. 4g, the Clinical Trial Directive provides that clinical
trials must be designed to “minimize pain, discomfort, fear,
and any other foreseeable risk in relation to the disease and
developmental stage”. The requirement that the degree of
distress and risk threshold have to be constantly monitored,
captured in the same article, demonstrates the importance of
this provision, as conformity with most requirements in the
Clinical Trial Directive is only assessed at a single moment
in time. In addition, the well known general principle that the
interests of the patient always prevail over those of science
and society is adopted in art. 4i of the Directive. Somewhat
notable, this provision is subsumed in the speciﬁc provisions
on clinical trials on minors.
4.2.5. Pediatric expertise
According to art. 4h of the Clinical Trial Directive,
ethics committees that assess studies involving minor research
subjects must include a member with pediatric expertise,
or gain advice about the clinical, ethical, and psychosocial
problems in the ﬁeld of pediatrics before deciding upon the
research protocol.
4.3. Pediatric regulation
Even though the Clinical Trial Directive was a milestone in
the facilitation of clinical trials, further legislative initiatives
were needed to address the poor interest in developing drugs
for the young. To correct the disinterest of industry in
developing and marketing drugs for children, the Pediatric
Regulation requires that clinical trials in minors are planned
and conducted for all new products entering the market. In
addition, the Pediatric Regulation offers considerable rewards
for the conduct of clinical trials in minors, in the form of
prolongation of market exclusivity.
In contrast to the European Convention and the European
Directive, the Pediatric Regulation is entirely dedicated to
clinical research in minors. In art. 2,1 of the Regulation,
minors are deﬁned as the population aged between birth and
18 years of age.
The Pediatric Regulation does not speciﬁcally address
ethical issues related to the involvement of minor subjects in
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clinical research, but focuses on facilitation and encourage-
ment of pediatric drug development. The regulation requires
that for every request for marketing authorization, a Pediatric
Investigation Plan (PIP) is negotiated early in research (art.
7). This PIP is to ensure that the necessary data to use a drug
in all subsets of the pediatric population are gathered in the
clinical research preceding marketing authorization. However,
waivers and deferrals to this general rule are possible under
certain conditions. In addition, the conduct of pediatric re-
search is stimulated with strong incentives, as drugs tested
in children obtain an extension of market exclusivity of six
months (art. 36). Also for off-patent drugs, research in mi-
nors is rewarded by means of the ‘pediatric use marketing
authorization’ (PUMA). To organize the assessment of PIPs,
waivers, and deferrals, art. 3 of the Pediatric Regulation man-
dated the establishment of a Pediatric Committee (PDCO),
having as its main tasks the assessment of PIPs, waivers,
and deferrals, and to support and advise the Agency and
Commission.
5. Regulation at the national level of EU member states
At the level of EU member states, national regulation set
out the conditions in which pediatric clinical research can
be conducted in the territory of the nation in question. The
requirements captured in the national legislation of an EU
member state, however, can diverge from the requirements
captured in the regulatory framework at the supranational
level or be applicable supplementary to the provisions in the
directive.
The analysis of domestic regulatory requirements will
focus on the implementation of the Clinical Trial Directive in
the national legislation of EU member states. Like the analysis
of the regulation at the supranational level, the analysis of
the domestic legislation of EU Member States will focus on
the ﬁve major ethical issues in pediatric clinical trials that are
regulated: (a) informed consent, (b) the necessity to involve
minors in research to obtain relevant results, (c) the interests
of minors in research participation, (d) the potential risks
and burdens related to clinical trial participation, and (e) the
pediatric expertise of ethics committees.
5.1. Informed consent
Article 4 of the Clinical Trial Directive addresses the spe-
ciﬁc issue of informed consent to enroll a minor in a clinical
study and sets down several requirements for the consent to
enroll a minor in a clinical trial. First, proxy consent must
be provided by the parents or another legal representative.
This consent may be revoked at any time without negative
consequences to the minor concerned, and must represent the
presumed will of the minor. Second, the minor concerned
must receive information regarding the trial, the risks and
the beneﬁts, appropriate to his/her capacity of understanding,
and provided by staff with experience with minors. Third,
the explicit dissent to start or continue research participation
expressed by a minor who is capable of forming an opinion
and assessing the information relevant to participation in the
clinical trial, must be considered by the (principal) investiga-
tor at any time. Fourth, no incentives or ﬁnancial inducements
may be provided except for compensation.
Among the different domestic laws that implement the
Clinical Trial Directive into the national law of individual
member states, diversity exists regarding all four requirements
for valid informed consent. In addition, several EU Member
States speciﬁcally deﬁne age criteria or an age cut-off with
regard to the decision making capabilities of minor research
subjects.
5.1.1. Age criteria
The Clinical Trial Directive does not specify an age cut-
off for medical majority. However, as a general rule, all
individuals who have not reached the age of 18 years can be
regarded as minors in decisions concerning their participation
in a clinical trial. Nonetheless, several EU member states
deﬁne speciﬁc age criteria that deviate from this general rule
(Table 2 provides an overview of the age cut-offs that are
applicable in different EU Member States). For example, in
Ireland, Lithuania and the United Kingdom, all individuals
who have not yet reached the age of 16 years are considered
minors. Alternately, several EU Member States distinguish
between two age groups, each of which is subjected to
speciﬁc requirements for informed consent. The age criterion
that is used to distinguish age groups varies signiﬁcantly,
ranging from 7 to 15 years of age. For example, in Estonia,
the group of minors up to 6 years of age is differentiated
from minors aged 7–17 years. In the Netherlands and Spain,
the age of 12 is used as an age cut-off. The Bulgarian act
differentiates between “children” (being minors up to 14 years
of age) and “young persons” (being minors aged 14 to 18
years old). Also in Hungary, an age cut-off of 14 years of
age is applicable. Persons under the age of 14 are considered
as legally incompetent, persons aged 14 and older have a
“limited competency”, similar to adults that are placed under
limited guardianship [6]. The Finnish act distinguishes minors
up to 14 years of age from minors aged 15 and older. Also
Denmark distinguishes minors under the age of 15 from
minors aged 15 to 17 years old. In Poland, the age of 16 is
used as an age cut-off.
5.1.2. Proxy consent representing the presumed will of the
minor
The Clinical Trial Directive requires that proxy consent has
been obtained from the parents or another legal representative
prior to enrolling a minor subject in a clinical trial. This
consent can be withdrawn at any time without detriment to
the minor (e.g. by a decrease in the current level of care),
and must represent the presumed will of the minor. This last
requirement, however, is very confusing, as it is neither clear
what constitutes the presumed will of the minor, nor how this
presumed will (or violations to it) can be determined.
Within the domestic law of EU Member States, con-
siderable variation in requirements regarding proxy consent
representing the presumed will of the minor can be found.
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Table 2
Overview of Age Criteria in the National Laws implementing the Clinical Trials Directive
Age
cut-off
Minors aged younger than the age criterion: Minors aged older than the age criterion:
Bulgaria 14 consent must be provided by both parents or the legal
representative
must grant their consent in addition to the consent
provided by the parents or another legal guardian
Denmark 15 consent must be provided by the parents or legal representative can in some instances consent to research participation
without consent provided by a parent or another legal
representative, if the ethics committee grant an exception
hereto.
Estonia 7 consent must be provided by the parents or legal representative must grant their consent in addition to the consent
provided by the parents or another legal guardian
Finland 15 consent must be provided by the parents or legal representative.
In the case minors who are capable of understanding the
importance of the research procedure, they must provide written
consent in addition to the parents
can consent for clinical research participation. The parents
or another legal representative must be informed, but not
consent, provided that the minor is capable of
understanding the important of the research procedure,
and the research is of direct beneﬁt.
Hungary 14 consent must be provided by the parents or legal representative must not provide consent. The consent of the parents or
legal representative is sufﬁcient.
Ireland 16 consent must be provided by the parents or legal representative are regarded as competent adults in decisions on clinical
research participation
Lithuania 16 consent must be provided by the parents or legal representative
and the children’s rights protection agency of a district or a city
are regarded as competent adults in decisions on clinical
research participation
Netherlands 12 consent must be provided by the parents or legal representative must grant their consent in addition to the consent
provided by the parents or another legal guardian
Poland 16 consent must be provided by the parents or legal representative must grant their consent in addition to the consent
provided by the parents or another legal guardian
Spain 12 consent must be provided by the parents or legal representative must grant their consent in addition to the consent
provided by the parents or another legal guardian
United Kingdom 16 consent must be provided by the parents or legal representative are regarded as competent adults in decisions on clinical
research participation
First, several member states specify who must grant informed
consent. The Bulgarian act emphasizes that consent must
be provided by both7 parents or the legal guardians of the
subject. Also in France, both parents must grant their consent,
except in the case that (a) the research only entails minimal
risk and minimal burden without detriment to the medical
treatment of the minor, (b) the research is conducted on the
occasion of medical treatments, or (c) one of the parents can-
not give his/her authorization within time limits compatible
with the methodological requirements of the trial concerned.
According to the Italian decree, the informed consent of one
of the parents or a legal representative must be obtained.
However, when both parents are present they both have to
grant their informed consent. In Latvia, the informed consent
of (at least one of) the parents or a legal representative is
required. In Lithuania, informed consent must be given by
both parents or another legally acceptable representative of
the minor, and the children’s rights protection agency of a
district or a city. However, when the parents of a minor are
divorced, the consent of one of the parents or of the legally
7 One parent sufﬁces when one of the parents is unknown, deceased or
deprived of parental rights or, when in the case of divorce no such rights
have been assigned.
acceptable representative and of the district or city children’s
rights protection agency sufﬁces.
Depending on the age cut-off deﬁned in domestic legis-
lation, the consent of a minor may be required in addition
to the proxy consent granted by the parents. According to
the Estonian implementation of the Clinical Trial Directive,
minors aged 7 to 17 years old must grant their consent in
addition to the consent of the legal representative before en-
tering a clinical trial. In the Netherlands, minors aged at least
12 years must grant their informed consent complementary to
the consent of the parents or another legal guardian, unless
the minor subject cannot be deemed capable of reasonably as-
sessing his or her interests in participating in the clinical trial.
Also in Spain, minors aged twelve or older must give their
consent to take part in the trial. In Bulgaria, young persons
(aged 14 to 18 years old) must provide their informed consent
in addition to (both) parents or the custodian. In Hungary,
minors with limited competency (aged 14 and older) must
not grant their informed consent in addition to the consent
provided by a close relative or a legal guardian. Thus, the age
cut-off used in Hungary to discern incompetent minors from
minors with limited competency does not have any impact on
the consent process [6]. In Finland, minors under the age of
15 years who are capable of understanding the importance
of the research procedure to be carried out on them must
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provide written consent in addition to the proxy consent given
by their guardian or legal representative. For minors aged
15 and older surrogate consent is not required, provided that
the minor is capable of understanding the importance of the
research procedure (taking account of the age and maturity of
the minor) and the research is likely to be of direct beneﬁt to
the minor’s health. Here, the written consent of the minor is
sufﬁcient, although the guardian must be informed about the
participation of the minor in the clinical trial. In Denmark, the
ethics committee may grant exemptions from surrogate con-
sent for minors aged 15 and older. It is emphasized that this
exemption shall be granted with due regard to the nature, risk
and harmfulness of the project. The exemption of surrogate
consent does not rule out the holder of the custody, as it is
emphasized that the holder of the custody must receive the
same information and must be involved in the decision of the
minor. In Poland, minors aged 16 or older must grant written
consent in addition to the consent of the parents or another
legal representative, in so far that the minor concerned is
capable of expressing a conscious opinion about participation
in the research concerned.
The Greek law does not use a ﬁxed age cut-off, but requires
that minors who are capable of comprehending the essence
of the clinical trial grant their written consent in addition to
the consent of the parents or the legal representative. This
is also the case in Germany, where minors who are capable
of understanding the nature, signiﬁcance and implications of
the clinical trial and who are capable of forming a rational
opinion regarding participation in the trial must grant their
informed consent in addition to the proxy consent granted by
the legal representative. In addition, the German law clariﬁes
that consent must only represent the presumed will of the
minor whenever such a will can be ascertained. In the Czech
implementation of the Clinical Trial Directive, it is stated
that consent must be respectful to the minor’s age and/or
intellectual capacity.
The Austrian act requires that consent has been obtained
from minor research subjects in so far the minor concerned
is capable of making rational decisions and of understanding
the importance, scope, and risks of the trial. This consent
is complementary to the consent provided by the legal
guardian. In France, minors must be consulted according to
their capacity of understanding and their assent for research
participation must be sought. Finally, the Estonian Act
provides that proxy consent must not always be respected. For
minors who have not reached the age of 7, the proxy consent
to enroll the minor in a clinical study must not be adhered
to by researchers if the decision of the legal representative
clearly violates the interests of the child concerned. This
provision however, seems completely redundant, as there are
no valid reasons for involving minors in research that clearly
violates their interests, even if the parents would be prepared
to consent to such research. In addition, parental consent
never obliges researchers to enroll a minor in a study, since
there is no such thing as a generally recognized right to be in
a clinical trial.
5.1.3. Information provided to the minor
The Clinical Trial Directive stipulates that minors must
receive information according to their capacity of understand-
ing, from staff with experience with minors, regarding the
trial, the risks and the beneﬁts. Obviously, this general for-
mulation leaves much to the discretion of those implementing
the provisions of the Clinical Trial Directive, including the
legislators of the 27 EU member states. Member states vary
considerably with regard to age criteria, the content of the
information, the person providing the information and the
veriﬁcation of understanding.
First, several EU Member states relate requirements to
provide information to the age of minor subjects. In Estonia,
children aged 6 or younger must, to a reasonable extent, be
informed about the clinical trial and the decisions made. In the
Netherlands, minors under the age of twelve and other minors
that are not capable of consenting to research participation
must be told what is to happen in a way they are able to
understand. According to Swedish law, minor subjects who
have reached the age of 15 must be provided with information
about the trial and consent to research participation in so far
that they realize what their part in the research entails.
Second, several EU member states provide detailed re-
quirements about the content of the information provided. In
Germany, both minors and their legal representative should
be offered a counseling session with an investigator about
conditions surrounding the conduct of the clinical trial. Ac-
cording to the Irish statutory instrument, informed consent
must be preceded by an interview with the investigator (or
another member of the investigating team) in which he or
she has been given the opportunity to understand the nature,
objectives, risks and inconveniences of the trial and the con-
ditions under which it is to be conducted. In Ireland and the
UK, the person with parental responsibility must have been
provided with a contact point where further information about
the trial can be obtained prior to granting informed consent.
The Czech Decree on Good Clinical Practice speciﬁes that
the information provided to the minor must include infor-
mation about possible discomfort and potential problems, be
provided in writing and be speciﬁcally tailored to the level of
understanding of the minor whenever possible.
Third, details on the person providing the information are
given in the domestic implementation of the Clinical Trial
Directive of several EU member states. In this respect, the
Danish law stipulates that the information be provided by
a person that is familiar with the trial and possesses the
educational qualiﬁcations to communicate with minors of
the age group in question. The Irish legislation requires that
consent is given in consultation with the registered medical
practitioner who has been treating the minor.
Finally, several EU member states require that the under-
standing of information is veriﬁed. In the Netherlands, the
party conducting the research must ensure that the person
from whom consent is requested is informed of (a) the aim,
nature and duration of the research, (b) the risk of participat-
ing in the trial and of withdrawing participation prematurely,
and (c) the burdens involved in research participation before
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the consent is granted. In addition, this information must be
provided in such a way that there is no reasonable doubt that
it has been understood by the recipient, and the recipient must
be given sufﬁcient time to consider the information properly
and to reach a reasoned decision. According to the Slovak
implementation of the Clinical Trial Directive, the investiga-
tor must verify that (a) the minor has expressed the will to
participate in the trial and is aware of his/her right, (b) is
capable of forming an opinion and evaluating the information
provided, and (c) is aware of the right to refuse or withdraw
participation at any time, without negative consequences.
5.1.4. Explicit dissent
According to art. 4(c) of the Clinical Trial Directive, the
explicit wish of a minor to refuse participation in a clinical
trial or to be withdrawn from a clinical trial is to be considered
at any time during the trial by the (principal) investigator,
in so far the minor concerned is capable of forming an
opinion and assessing the information provided. Obviously,
the obligation to “consider” the explicit dissent of the minor
is open to various interpretations. Several EU Member States,
however, narrow this broad formulation.
In Belgium, the Czech Republic, Germany, France, Fin-
land, Greece, the Netherlands, and Sweden, the explicit
dissent of a minor must be considered and respected. How-
ever, the Finnish law nuances that the age and maturity of the
minor must be taken into account in this matter. The Swedish
law explicitly adds that the dissent of a minor must also be
respected in the case that informed consent has been obtained
from the minor’s guardians.
The Bulgarian law requires that the expressed dissent of
young persons (i.e. minors aged 14 to 18 years old) is taken
into account by the (principal) investigator. However, since
according to the Bulgarian law, young persons must provide
their informed consent prior to research participation, the
function of this provision is unclear.
5.1.5. No incentives other than compensation
The EU has a clear policy with regard to the payment
of minor research subjects. In conformity with art. 4(d)
of the Clinical Trial Directive, no incentives or ﬁnancial
inducements except for compensation may be granted to
reward research participation. This requirement is adopted
(nearly) verbatim in all domestic implementations of the
Clinical Trial Directive.
Latvia adds in its domestic implementation of art. 4(d) of
the Directive that also compensation in the event of injury or
death attributable to research participation may be provided to
the minor. However, such compensation cannot be regarded
as an incentive, and therefore this addition is not relevant and
rather confusing. Likewise, in the Slovak implementation of
art. 4(d) of the Clinical Trial Directive, it is stipulated that
ﬁnancial motives, ﬁnancial or other material advantages apart
from indemniﬁcation are forbidden.
5.2. Necessity to involve minors
Minors are widely regarded as a vulnerable population
that deserve extensive protection against harm and abuse.
Therefore, minors should not be exposed to the risks to harm
and abuse that are inherent to any clinical trial, unless this is
strictly required to generate relevant research results for the
beneﬁt of minor patients (cf. infra).
In art. 4(e), the Clinical Trial Directive requires that the
involvement of minors be absolutely necessary to validate data
obtained in clinical trials on persons able to give informed
consent or by other research methods, and that research in
minor subjects either relates directly to a clinical condition
from which the minor concerned suffers, or be of such a
nature that it can only be carried out on minors.
Although, theoretically, necessity is a term that is open
to various interpretations, the term appears to be understood
uniformly in the European legislative landscape, as no signif-
icant variation in domestic provisions regarding the necessity
of involving minors in clinical research can be found in the
legislation of individual EU member states.
5.3. Interests of minor research subjects
Two provisions of the Clinical Trial Directive incorporate
the requirement to serve the interests of minor research sub-
jects. First, it is required that the clinical research generates
“some direct beneﬁt for the group of patients”. The interpre-
tation of this puzzling requirement is hampered by the many
ambiguities it entails, as a direct beneﬁt is by deﬁnition a
beneﬁt to the research subject concerned and thus not to a
group of individuals, and because research subjects are not
necessarily patients, and patients are not necessarily minors
[19]. Unfortunately, these ambiguities are not cleared up in
the domestic implementations of the Clinical Trial Directive
of EU member states. Second, it is required that research
either relates directly to a clinical condition from which the
minor concerned suffers, or be of such nature that it can only
be carried out on minors.
Several member states specify the requirements captured
in the Clinical Trial Directive. In Austria, investigational
medicinal products must be used in accordance with the
latest state of the art of medical science, diagnose, cure,
alleviate, or prevent minors from illnesses. Likewise, the
Bulgarian act stipulates that the tested medicinal product
must be designed for diagnosis, treatment or prevention of
diseases that is speciﬁc to children and young persons. The
Czech Health Act provides that research in minors must be
expected to generate preventive or therapeutic beneﬁts for
the participating subjects and generate a direct beneﬁt for
a group of patients. According to the French Public Health
Code, research can only be conducted in minors when the
expected beneﬁt to the participating subjects is likely to
justify the foreseeable risks. Alternately, also a beneﬁt for
other minors may justify the risk that the research entails. In
Germany, medicinal products can only be tested in minors
if they are intended to facilitate diagnosis or prevention of
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diseases in minors. In addition, the German act requires that
investigational medicinal products are indicated according to
the ﬁndings of medical science to save the life of the person
concerned, to restore a subject’s health, or to alleviate his or
her suffering, unless the trial is of direct beneﬁt to the group
of patients suffering from the same disease as the subject
concerned.
In Estonia, the broad and unclear requirement to generate
some direct beneﬁt for the group of patients is narrowed
as, according to the Estonian act, pediatric clinical trials
of investigational medicinal products must be expected to
generate a direct beneﬁt to the research subject. Also in
Lithuania, it is required that the research results have the
potential to produce a real and direct beneﬁt to the health
of the research subjects themselves, rather than a group of
patients. In the Netherlands and Hungary, clinical research
may not be conducted in minors under 18 years of age unless
the research is of direct beneﬁt to the subjects. However, the
requirement to generate a direct beneﬁt is linked to a speciﬁc
risk threshold: research with negligible risks and minimal
burden for the minor subject concerned may be conducted,
also in the absence of a direct beneﬁt to the research subject.
5.4. Risks and burdens
In art. 4(g), the Clinical Trial Directive requires that
clinical trials must be designed to minimize pain, discomfort,
fear, and any other foreseeable risk in relation to the disease
and developmental stage. In addition, the risk threshold and
degree of distress must be specially deﬁned and constantly
monitored.
Several EU member states provide additional details con-
cerning the risks and burdens involved in pediatric clinical
research. In this respect, the Belgian law provides that re-
search risks may not be disproportionate to the expected
beneﬁts. More generally, the Finnish Medical Research Act
requires that the risks involved in research are limited. Like-
wise, the Lithuanian law requires that biomedical research
does not pose risks to the health or life of vulnerable research
subjects.
Germany has a more restrictive policy than the Clinical
Trial Directive. The German act speciﬁes that clinical research
may only cause minimal risk and minimal burden to the
minor concerned. Moreover, the German act stipulates that
a research intervention only entails (i) minimal risk if this
intervention will result, at most, in a very slight and temporary
impairment of the minors’ health, and (ii) minimal burden
when it is to be expected that the discomfort for the minor
will be, at most, temporary and very slight. Also in the
Netherlands, pediatric clinical research that does not generate
a direct beneﬁt to the subjects participating in the trial may not
cross the thresholds for minimal risk and minimal burden. The
Austrian act requires that the beneﬁts to the subject concerned
outweigh the risks involved, unless when the trial (i) aims at
generating a substantial progress in scientiﬁc understanding
of the condition, disease, or disorder from which the minor
suffers and therefore is likely to beneﬁt the patient or group
of patients to which the minor belongs, and (ii) only entails
minimal risk and minimal burden.
5.5. Pediatric expertise of Ethics Committees
The legislator has assigned research ethics committees
an essential task in checking the compliance of research
protocols with the ethical legal requirements captured in
the Clinical Trial Directive. For the assessment of pediatric
research protocols, the Clinical Trials Directive explicitly
requires in art. 4(h) that ethics committees either have
pediatric expertise, or take advice in clinical, ethical and
psychosocial problems in the ﬁeld of pediatrics.
Several EU member states provide speciﬁc requirements
with regard to this pediatric expertise. In France, pediatric
expertise in ethics committees is required in so far research
concerns subjects aged 16 years or less, and only when
the ethics committee concerned has no pediatrician among
its members. In Italy, it is required that ethics committees
include a pediatrician among their members. The Belgian
law stipulates that Ethics committees that assess and endorse
pediatric protocols must include at least two doctor-specialists
in pediatrics, or take advice from two doctor-specialists in
pediatrics on the clinical, ethical, and psychosocial aspects
of the protocol. In Bulgaria, the consultation of external
experts in pediatrics by the ethics committee is mandatory
for all clinical trials in children or young persons. Likewise,
in Denmark, it is required that ethics committees that assess
protocols for pediatric clinical trials take advice from an
expert in pediatrics. The Czech Decree Good Clinical Practice
requires that ethics committees perform their supervision
in at least six-monthly intervals. Ethics committees lacking
experience in pediatrics must involve a specialist qualiﬁed in
pediatrics for the purposes of this supervision. Four member
states, Finland, Slovakia, the Netherlands, and Italy, have
ethics committees that are speciﬁcally devoted to minors [7].
6. Discussion
Throughout the past decades, considerable effort has been
made to harmonize the legal framework governing clinical
trials in the EU. Hereby, attention has been paid to the
speciﬁc issues in pediatric research. Particularly the European
Clinical Trial Directive is a milestone in the harmonization
of good clinical practice guidelines and legal requirements
for conducting clinical research in minors. As such, the
European Clinical Trial Directive is an important instrument
in efforts to facilitate pan-European multicentre pediatric
research. Nonetheless, the harmonizing capacity of the Euro-
pean Clinical Trial Directive is profoundly compromised by
three factors. First, apart from the Clinical Trial Directive,
also the European Convention and the Pediatric Regulation
govern the conduct of pediatric clinical trials in Europe at the
supranational level. This supranational legal framework in its
entirety, however, contains various unclear and contradictory
provisions, which complicate the implementation of this legal
framework. Second, a Directive, in contrast to a European
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Regulation, must be implemented into domestic law by all EU
Member States. As such an implementation is not necessarily
a servile copy of the original text of the Directive, the imple-
mentation process may create diversity within the European
legal landscape. Third, not everything in the law is arranged
by law, and the legal frameworks, both at supranational and
at national level, leave a lot of the interpretation and imple-
mentation of the legal frameworks to those who are actually
involved in the conduct of pediatric research.
First, a comparative analysis of the three main documents
of the European legal framework at the supranational level
reveals that this framework lacks internal consistency. Con-
tradictory provisions between the different documents, for
example with regard to provisions on the conduct of non-
beneﬁcial research and the veto-power of minors in decisions
about research participation, render it difﬁcult to interpret
and implement the European supranational legal framework.
Regarding non-beneﬁcial research, art. 17,2 of the European
Convention requires that in the absence of a direct beneﬁt
to the individual research participant, a minor can only be
involved in research if the study only entails minimal risks
and minimal burden, while art. 4e the Clinical Trial Directive
only requires ”some direct beneﬁt”’ to the research subject
or a related group of beneﬁciaries. This indicates that the
European Convention endorses a more restrictive policy than
the European Directive. As a consequence, early stage drug
development may be compromised in Member States that
have signed and ratiﬁed the European Convention. Also in
relation to the power of a minor to veto participation in
clinical research, contradictory provisions exist. While art. 4c
of the Clinical Trial Directive provides that the (principal)
investigator must consider the explicit wish of a minor to
refuse or discontinue participation (in the case of a minor
that is capable of assessing information and forming an
opinion), art. 17,1v of the European Convention provides that
minors cannot be involved in a study whenever they object to
research participation. Thus, theoretically, the European Con-
vention grants minors more extensive decision making powers
than the European Directive. In addition to these contradic-
tory provisions, the European legal framework also contains
numerous contingencies that require extensive interpretation.
It is for example not clear what must be understood as an
acceptable risk–beneﬁt ratio, what it means to “consider” the
explicit dissent of a minor, how the capacity of minors to
make decisions can be assessed, or why the Clinical Trial
Directive designates minor research participants as “patients”
and links beneﬁts to the “group of patients”.
Second, to a certain extent, the domestic implementation
of the clinical trial directive works against harmonization,
as Member States are free to vary the original text and
stipulate additional legal requirements, provided the standards
of protection and time limits captured in the European Clinical
Trial Directive are not violated.
The analysis of the domestic implementation of the Clin-
ical Trial Directive in the 27 member states of the EU
presented in this article shows that the domestic imple-
mentation creates considerable legislative diversity. However,
despite these variations in national provisions, few of the do-
mestic implementations of the Clinical Trial Directive appear
to be a major obstacle to pediatric clinical trials. In general,
research protocols can be tailored to comply with national
legal requirements of a Member State relatively easily, pro-
vided that one takes notice of the domestic provisions of an
individual Member State. Nonetheless, there is still a long
way to go in making all national requirements of individual
EU member states accessible, due to a lack of authorized
translations and easily accessible compilations of all legal
requirements.
Third, not everything in the law is arranged by law.
Particularly the role of individual decision makers in the
interpretation and implementation of European legal frame-
works can hardly be overestimated. These decision makers
can be institutional bodies (for example ethics committees,
or competent authorities) or persons (for example clinicians,
minors and their parents or legal representatives).
As the European legal framework leaves considerable dis-
cretion in the interpretation and application of regulatory
requirements individual and institutional decision-makers, the
implementation of this legal framework becomes largely de-
pendent upon the bodies and/or individuals who actually
decide on the involvement of an individual minor in a clinical
trial. Applying the same set of rules does not guarantee
a similar interpretation or application of these rules, and
therefore the discretionary freedom of decision-makers in
the setting of pediatric clinical research provokes a certain
diversiﬁcation of the regulatory landscape. The diversity in
implementation of regulatory requirements, however, entails
harsher consequences than the diversity of legal provisions
itself because of their practical impact. Rendering the im-
plementation of regulation dependent upon the discretion of
individuals that decide upon the accessibility and execution
of a research protocol, tends to make the implementation of
legal requirements a poorly intelligible process, the outcome
of which often appears hard to predict.
While it is true that the European legal frameworks that
govern pediatric clinical research by their nature generate a
considerable diversity in their actual interpretation and im-
plementation, this diversity need not become an enemy to
be defeated. Quite the reverse, the diversity in interpretation
and application of the legal frameworks governing pediatric
clinical research can be regarded as a considerable asset for
several reasons. First, research is not an impersonal enterprise.
Taking the personal concerns of clinicians, minors and their
parents seriously, however, can hardly be done in a regulatory
environment that fails to tolerate a certain level of diversity.
Second, research is not a universal enterprise. The demo-
graphic, institutional, economic, and cultural particularities of
individual member states are relevant to the design and con-
duct of pediatric clinical studies. Apparently uncomplicated
environmental factors, such as research infrastructure may
deeply affect the conduct of pediatric research. Consequently,
locality matters.
Therefore, the way forward in pediatric clinical research
rather seems one of dealing with diversity than one of seeking
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further operational harmonization. Nonetheless, certain con-
tradictory provisions should be rectiﬁed urgently. In particular,
the contradiction in the stance towards non-beneﬁcial research
between the European Convention and the Clinical Trials
Directive should be resolved. This should be feasible, because
now that the Clinical Trial Directive has been governing pedi-
atric clinical trials for more than ﬁve years, we should be able
to assess whether the more tolerant approach of the Clinical
Trial Directive in comparison to the European Convention has
permitted unethical research conduct. To our knowledge, no
incidences have been reported in this respect. Therefore, it
is doubtful whether abolishing the minimal risk and minimal
burden thresholds would impair ethical research conduct or
decrease the level of protection of research subjects. If the
minimal risk and minimal burden threshold, however, do not
contribute to increased ethical standards in pediatric clinical
research, they may be considered an obstacle that works
against the key objective of encouraging and facilitating
clinical studies in children.
Although further harmonization can solve certain issues,
handling diversity will be indispensible in a landscape as
diverse as the EU. Operational strategies to manage this
diversity, however, remain largely unexplored to date.
7. Recommendations for the conduct of clinical trials in
minor CF patients
7.1. A shared responsibility
The ethical conduct of clinical research is a shared
commitment of all those involved. Obviously, the approval
of a research protocol is by no means a full guarantee for
clinical research to be ethically sound. Therefore, all parties
involved have a responsibility in assessing the acceptability
and appropriateness of the research, in general, and for the
subject concerned, from their own, unique perspective.
Although the European legal framework only draws ex-
plicit attention to permission in the form of protocol approval
and informed consent, clinicians have an important role. They
must assess whether research participation is medically rec-
ommendable to the subject concerned. When the researcher is
also the patient’s physician, their knowledge of the patients’
medical and personal background aids greatly this assessment.
7.2. Walking the thin line
The regulations that govern pediatric clinical research in
the EU address ethical issues in research participation de-
tached from the therapeutic context in which clinical trial
participation is often discussed. In practice, however, the
dividing line between research and therapy is often extremely
thin. Therefore, dealing with the ambiguous distinction be-
tween research and therapy is essential for good clinical
practice.
While framing clinical research in the therapeutic context
of the minor concerned offers unique opportunities to clarify
the relevance of the proposed research for the individual
minor, integrating research in a therapeutic framework may
at the same time blur the dividing line between research and
therapy. Therefore, it is of key importance that research is also
distinguished from therapy, even when it is discussed against
a therapeutic background. In this respect, it is particularly
important to communicate what the patient is to expect after
the trial has been terminated.
7.3. It’s all about the minor
Conducting research in minors is all about minors. There-
fore, minors who are eligible research subjects should have
a central position and sometimes also an active role in the
consent discussion, reﬂecting their personal desire to take part
in the decision, and their maturity and developmental stage.
Notwithstanding this central role of the minor, the main
responsibilities in deciding upon the enrollment of a minor in
a clinical trial are in the hands of the adults surrounding them.
These are in the ﬁrst place the parents or legal guardians that
hold the legal capacity to grant informed consent for research
participation, but also their physicians and the researchers that
invite them to participate in the clinical trial. All involved
should strive to move beyond their personal convictions, and
aspire to decide in the interests of the minor concerned.
7.4. Validate experience
In the speciﬁc case of clinical research on CF patients, it
should be taken into account that due to the chronic nature of
this disorder and its impact on their lives, young CF patients
may already have developed above-average decision making
skills. Therefore, they should not be underestimated in their
capacity to participate. Moreover, the experience that minor
patients already have and will create in the near future should
be taken into account.
It should be acknowledged that throughout the years, CF
patients are frequently invited to participate in studies. Clin-
icians should therefore guard against individual CF patients
participating too frequently in clinical studies to prevent them
from becoming research guinea pigs. On the other hand, inor-
dinate enthusiasm for clinical trials may create the impression
that research subjects are elected to be the ﬁrst beneﬁciaries
of novel and important medical breakthroughs. This should
also be avoided.
7.5. In between the lines
The supranational and national legal frameworks that
govern pediatric clinical trials set down general requirements
for the conduct of studies in minor research subjects. To a
large extent, the interpretation and implementation of these
frameworks, however, is not arranged by law but left to the
discretion of those who are directly involved in the conduct
of clinical trials. Here, obviously, clinicians hold an expertise
and experience that is disproportionately large in comparison
to that of minors and their parents. Therefore, they have a
vital role in the realization of good clinical practice.
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Giving shape to poorly deﬁned ethical and legal require-
ments is a complex task, that should not be reduced to the
responsibility of a single individual. Therefore, it is recom-
mended that ethical issues in the conduct of clinical research
are discussed among colleagues, and that the created expertise
in dealing with these issues is shared over individual trials.
7.6. Incorporate trust
The fact that clinicians, minors, and their parents (or
another legal representative) are assigned a considerable
role in the interpretation and implementation of the legal
framework renders the relationships between these actors of
vital importance. Within these relationships, trust is essential,
from the moment of recruitment to the termination of the
trial, to bridge the asymmetry in knowledge, expertise, and
commitment of the different parties involved.
However, despite the fundamental importance of trust in
the mutual relationships between clinicians, minors, and their
parents (or other legal representative), also the downside of
trust must be acknowledged. Trust is not infallible, can be
very naïve, and may open minor research subjects to the pos-
sibility of coercion and abuse. Therefore, it is necessary that
safeguards against inordinate loyalty, deception, therapeutic
misconception and other ethical digressions are incorporated
in clinical practice. Rather than having outsiders bringing in
such safeguards, expertise should be created both in clinicians
who communicate about the trial and in minors and parents
who consider enrollment into a clinical trial.
7.7. Pediatric expertise
The ethical and legal frameworks that govern pediatric
research in the EU formally require that ethics committees
foster pediatric expertise, either by including a pediatrician
among their members or by calling in external advice. Al-
though it is clear that individual pediatricians are to embody
this pediatric expertise (who), it is neither clear what such
pediatric expertise entails contentwise (what), nor what added
value such expertise should bring to the assessment of re-
search protocols (why). Therefore, both the content and the
aims of pediatric expertise in pediatric research should be
cleared out. Hereby, it must be acknowledged that the individ-
ual pediatricians who embody the pediatric expertise of ethics
committees may lack speciﬁc knowledge on certain ethical
and legal aspects of their practice, no matter how experienced
they are. Therefore, it is essential that pediatricians who act as
an expert in ethics committees are provided with up to date,
clear and relevant research results on the ethical, legal, and
social issues in pediatric clinical research practice.
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